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Abstract 
Purpose: To synthesize a series of analogues of 1,3,4-oxadiazole and to evaluate their antibacterial 
activity. 
Methods: Ethyl piperidin-4-carboxylate (1) was mixed with 4-toluenesulfonyl chloride (2) in benignant 
conditions to yield ethyl 1-(4-toluenesulfonyl)piperidin-4-carboxylate (3) and then 1-(4-
toluenesulfonyl)piperidin-4-carbohydrazide (4). Intermolecular cyclization of 4 into 2-mercapto-5-(1-(4-
toluenesulfonyl) piperidin-4-yl)-1,3,4-oxadiazole (5) was obtained on reflux with CS2 in the presence of 
KOH. Molecule 5 was stirred with alkyl halides, 6a-i, in DMF in the presence of LiH to synthesize the 
final compounds, 7a-i. The structures of these molecules were elucidated by Fourier transform infra-red 
(FTIR) spectroscopy, proton nuclear magnetic resonance (1H-NMR) and electron impact mass 
spectrometry (EI-MS). Antibacterial activity was evaluated against five bacterial strains, namely, 
Salmonella typhi, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus 
subtilis, with ciprofloxacin used as standard antibacterial agent.  
Results: Out of nine synthesized derivatives, compound 7a was the most active against three bacterial 
strains, S. typhi, E. coli and P. aeruginosa, with minimum inhibitory concentration (MIC) of 9.11 ± 0.40, 
9.89 ± 0.45 and 9.14 ± 0.72 µM, respectively, compared with 7.45 ± 0.58, 7.16 ± 0.58 and 7.14 ± 0.18 
µM, respectively, for the reference standard (ciprofloxacin). Similarly, compounds 7a - 7c showed 
relatively good antibacterial activity against B. subtilis strain while compound 7e - 7g revealed good 
results against S. typhi bacterial strain. 
Conclusion: The results indicate that S-substituted derivatives of the parent compound are more 
effective antibacterial agents than the parent compound, even with minor differences in substituents. 
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Derivatives of 1,3,4-oxadiazole, aromatic 
heterocyclic class bearing two nitrogens and one 
oxygen, have demonstrated a broad spectrum of 
biological activities including anticonvulsant, anti-
depressant, anti-inflammatory, antifungal, 
hypoglycemic, antimitotic, antimicrobial, 
analgesic, insecticidal, herbicidal and anticancer 
activities [1-11]. Piperidine, derivatives are 
known for the therapeutic potential [12]. They 
have been employed to control insulin & glucose 
levels, cocaine abuse treatment, and as 
anesthetics [13]. The sulfamoyl bearing 
molecules, sulfonamides, have been used as 
antibacterial agents, anti-enzymatic agents to 
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cure different enzyme relating diseases, in 
chemotherapy of cancer, diuretics and 
hypoglycemia [14-16]. 
 
Scientists have been searching for new drug 
candidate for new infectious diseases of humans, 
plants and animals. In this field the derivatives of 
sulfonamide, oxadiazole especially 1,3,4-isomer 
and piperidine have earned much fame because 
of significant pharmacological activities, as 
referenced. Their biological activities prompted 
us to synthesize some new compounds of 1,3,4-
oxadiazole, piperidine and sulfonamide moieties 
after multi-steps and to evaluate them for 
antibacterial activity against two gram positive 






The synthetic grade chemicals were purchased 
from Sigma Aldrich, Alfa Aesar and Merck 
through local suppliers. The solvents were of 
analytical grade and used without purification. 
Single spot on pre-coated silica gel G-25-UV254 
aluminum plates in thin layer chromatography 
(TLC) was the initial tool for purity of compounds 
during and after the reactions. The TLC plates 
were developed in solvent system of ethyl 
acetate and n-hexane and observed under 254 
nm UV lamps. Griffin-George melting point 
apparatus was used to note the melting points 
using open capillary tube and were uncorrected. 
Jasco-320-A spectrometer was employed to 
record the IR spectra using KBr pellet method 
and wave number was mentioned in cm-1. Bruker 
spectrometer operating at 400 MHz was utilized 
to record the proton NMR spectra of the 
compounds dissolved in CDCl3 and chemical 
shifts were given in ppm. JMS-HX-110 
spectrometer was applied to record the EIMS 
spectra. 
 
Synthesis of ethyl 1-(4-toluenesulfonyl) 
piperidin-4-carboxylate (3) 
 
Ethyl piperidin-4-carboxylate (1; 15 mmol) was 
taken in 100 mL round bottom (RB) flask and 
suspended in 25 - 30 mL distilled water. 4-
Toluenesulfonyl chloride (2; 15 mmol) was 
gradually added by parts on continuous stirring. 
The mixture was allowed to stir for further 4 h 
and the pH was adjusted to 9-10 by aqueous 
Na2CO3 at room temperature (RT). On 
completion of reaction to quench the precipitates 
a few drops of dilute HCl were added to the 
reaction mixture on continuous shaking till pH of 
5-6 was adjusted. The precipitates were allowed 
to settle down for 0.25 h. The precipitates were 






late (3; 12 mmol) was homogeneously mixed 
with 25 mL MeOH in a 100 mL RB flask. The 
hydrated hydrazine (80 %, 12 mmol) was poured 
to the mixture and set to reflux for 5 h. After 
single spot on TLC, excess of distilled water was 
added along with shaking till precipitation. The 
product was separated through filtration, washed 





Compound 4 (10 mmol) was taken in 100 mL RB 
flask and mixed with 20 mL methanol. Then 10 
mmol KOH was dissolved in the mixture on 
reflux. The system was cooled to RT and 20 
mmol CS2 was added and again set to reflux for 
7 h. After confirmation by TLC, excess cold 
distilled water (about 40 mL) was added followed 
by dilute HCl to adjust pH at 5-6 and left the 
precipitates to settle down for 0.25 h. The 
precipitates of 5 were collected after filtration, 






The molecule 5 (0.2 mmol) was taken in 50 mL 
RB flask and dissolved in N, N-
dimethylformamide (DMF, 12 mL). Lithium 
hydride (0.2 mmol) was added and the mixture 
was stirred for 0.5 h at RT. Then alkyl halides 
(6a-i, 0.2 mmol) were added and set to stir for 4-
6 h. On completion of reaction, confirmed by 
TLC, excess chilled distilled water was added to 
gain the precipitates of final products, 7a-i, which 
were collected after filtration from aqueous 
medium, washed, dried and then subjected to 
antibacterial activity analysis. 
 
Antibacterial activity assay 
 
Two gram-positive bacterial strains and three 
gram-negative bacterial strains were clinically 
isolated and stored on agar medium to facilitate 
the bacterial growth. 20 µg test samples after 
dilution by suited solvents and 180 µL overnight 
maintained fresh bacterial cultures after suited 
dilution with fresh nutrient broth were mixed. 
Initial absorbance was observed and kept 
between 0.12 - 0.19 at 540 nm.  
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Scheme-1: Protocol for S-substituted derivatives of 2-mercapto-5-(1-(4-toluenesulfonyl) piperidin-4-yl)-1,3,4-
oxadiazole (5). Reagents and conditions: (I) water, sodium carbonate, stirring for 4 h (II) hydrated hydrazine, 
methanol, refluxing for 5 h (III) carbon disulfide, potasium hydroxide, methanol, refluxing for 7 h (IV) alkyl halides 
(6a-i), LiH, DMF, Stirred for 4 -6 h. 
 
Table 1: Different S-substituted alkyl groups 
 
Compound R Compound R 
7a CH2 CH3
1''' 2'''  
7f CH2 CH2 CH2 CH2 CH3
1''' 2''' 3''' 4''' 5'''  
7b CH2 CH2 CH3
1''' 2''' 3'''  
7g 
CH3
CH CH2 CH2 CH3
5'''






7h CH2 CH2 CH2 CH2 CH2 CH2 CH31''' 2''' 3''' 4''' 5''' 6''' 7'''  
7d CH2 CH2 CH2 CH3
1''' 2''' 3''' 4'''  
7i CH2 CH2 CH2 CH2 CH2 CH2 CH21''' 2''' 3''' 4''' 5''' 6''' 7'''
CH3
8'''  







Microplate with lid was incubated at 37 oC for 16 
- 24 h. Absorbance was noted at 540 nm using 
micro plate reader before and after incubation 
and the difference was noted as an index of 
bacterial growth. The percent inhibition was 
calculated using Eq 1. 
 
Inhibition (%) = (C-T)/C×100 ………………. (1) 
 
where C and T are absorbance of control and 
test compound, respectively. 
 
Results are mean of triplicate measurements (n 
= 3, ± SEM). Ciprofloxacin was taken as 
standard. Minimum inhibitory concentration (MIC) 
was measured with suitable dilutions (5 - 30 
µg/well) and results were calculated using EZ-Fit 
software (Perrella Scientific Inc. Amherst USA) 
[17].  
 
Statistical analysis  
 
All computations were executed in triplicate and 
statistical analysis was performed with Microsoft 
Excel 2010. The results are expressed as mean 
± SEM (n = 3). Minimum inhibitory concentration 
(MIC) was computed with suitable dilutions (5 - 
30 µg/well) for each sample and results 
calculated using EZ-Fit software (Perrella 
Scientific Inc, Amherst, USA). 
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Multifunctional compound 5 was synthesized 
successfully, this compound contained 1,3,4-
oxadiazole, sulfamoyl and piperidine moieties. 
The synthesis of the compound is represented in 
Scheme-1. Different S-substituted derivatives of 
compound 5 were synthesized in good yield. All 
these derivatives were screened for their 
antibacterial activity. The antibacterial studies 
proved compound 7a the most potent of all 
compounds under study while some other 
compounds showed relatively good antibacterial 





White amorphous solid; Yield: 89 %; M.P.: 70-72 
oC; Mol. formula: C15H21NO4S; Mol. weight: 311; 
IR (KBr, cm-1): υmax 3067 (Aromatic C-H), 1732 
(Ester C=O),1531 (Aromatic C=C), 1335 
(Sulfamoyl S=O), 1079 (Ester C-O); 1H-NMR 
(400 MHz, CDCl3,ppm): δ 7.62 (d, J = 8.0 Hz, 
2H, H-2'' & H-6''), 7.32 (d, J = 8.0 Hz, 2H, H-3'' & 
H-5''), 3.98 (q, J = 7.2 Hz, 2H, OCH2CH3), 3.71-
3.68 (m, 2H, He-2' & He-6'), 2.73-2.62 (m, 1H, H-
4'), 2.54-2.48 (m, 2H, Ha-2' & Ha-6'), 2.42 (s, 3H, 
CH3-4''), 2.10-2.08 (m, 2H, He-3' & He-5'), 1.60-
1.86 (m, 2H, Ha-3' & Ha-5'), 1.15 (t, J = 7.2 Hz, 
OCH2CH3); EIMS (m/z): 311 [M]+, 266 
[C13H16NO3S]+, 238 [C12H16NO2S]+, 184 






White crystalline solid; Yield: 91 %; M.P.: 128-
130 oC; Mol. formula: C13H19N3O3S; Mol. weight: 
297; IR (KBr, cm-1): υmax 3348 (Hydrazide N-H), 
3063 (Aromatic C-H), 1682 (Amide C=O), 1534 
(Aromatic C=C), 1339 (Sulfamoyl S=O); 1H-NMR 
(400 MHz, CDCl3, ppm): δ 7.61 (d, J = 8.0 Hz, 
2H, H-2'' & H-6''), 7.33 (d, J = 8.0 Hz, 2H, H-3'' & 
H-5''), 3.72-3.69 (m, 2H, He-2' & He-6'), 2.73-2.62 
(m, 1H, H-4'), 2.53-2.49 (m, 2H, Ha-2' & Ha-6'), 
2.42 (s, 3H, CH3-4''), 2.12-2.10 (m, 2H, He-3' & 
He-5'), 1.58-1.84 (m, 2H, Ha-3' & Ha-5'); EIMS 
(m/z): 297 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 





White amorphous solid; Yield: 87 %; M.P.: 230-
233 oC; Mol. formula: C14H17N3O3S2; Mol. weight: 
339; IR (KBr, cm-1): υmax 3067 (Aromatic C-H), 
2522 (Mercapto S-H), 1641 (Oxadiazole C=N), 
1541 (Aromatic C=C), 1345 (Sulfamoyl S=O), 
1249 & 1079 (Oxadiazole C-O-C); 1H-NMR (400 
MHz, CDCl3,ppm): δ 7.63 (d, J = 8.0 Hz, 2H, H-
2'' & H-6''), 7.32 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 
3.71-3.68 (m, 2H, He-2' & He-6'), 2.74-2.63 (m, 
1H, H-4'), 2.54-2.48 (m, 2H, Ha-2' & Ha-6'), 2.42 
(s, 3H, CH3-4''), 2.10-2.08 (m, 2H, He-3' & He-5'), 
1.59-1.85 (m, 2H, Ha-3' & Ha-5'); EIMS (m/z): 339 
[M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 184 






Fluffy white amorphous solid; Yield: 87 %; M.P.: 
184-186 oC; Mol. formula: C16H21N3O3S2; Mol. 
weight: 367; IR (KBr, cm-1): υmax 3065 (Aromatic 
C-H), 1645 (Oxadiazole C=N), 1563(Aromatic 
C=C), 1335 (Sulfamoyl S=O), 1249 & 1079 
(Oxadiazole C-O-C); 1H-NMR (400 MHz, 
CDCl3,ppm): δ 7.63 (d, J = 8.0 Hz, 2H, H-2'' & H-
6''), 7.31 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 3.69-
3.64 (m, 2H, He-2' & He-6'), 3.20 (q, J = 7.2 Hz, 
2H, H-1'''), 2.87-2.80 (m, 1H, H-4'), 2.60-2.54 (m, 
2H, Ha-2' & Ha-6'), 2.42 (s, 3H, CH3-4''), 2.12-
2.08 (m, 2H, He-3' & He-5'), 2.01-1.94 (m, 2H, Ha-
3' & Ha-5'), 1.43 (t, J = 7.2 Hz, 3H, CH3-2'''); 
EIMS (m/z): 367 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 
[C7H8NO2S]+, 155 [C7H7O2S]+, 91 [C7H7]+, 83 





White amorphous solid; Yield: 88 %; M.P.: 178-
180 oC; Mol. formula: C17H23N3O3S2; Mol. weight: 
381; IR (KBr, cm-1): υmax 3065 (Aromatic C-H), 
1645 (Oxadiazole C=N), 1531 (Aromatic C=C), 
1335 (Sulfamoyl S=O), 1249 & 1079 (Oxadiazole 
C-O-C); 1H-NMR (400 MHz, CDCl3, ppm): δ 7.62 
(d, J = 8.0 Hz, 2H, H-2'' & H-6''), 7.33 (d, J = 8.0 
Hz, 2H, H-3'' & H-5''), 3.68-3.65 (m, 2H, He-2' & 
He-6'), 3.18 (t, J = 6.8 Hz, 2H, H-1'''), 2.87-2.80 
(m, 1H, H-4'), 2.58-2.52 (m, 2H, Ha-2' & Ha-6'), 
2.42 (s, 3H, CH3-4''), 2.10-2.06 (m, 2H, He-3' & 
He-5'), 2.01-1.94 (m, 2H, Ha-3' & Ha-5'), 1.52-1.41 
(m, 2H, H-2'''), 0.95 (t, J = 7.2 Hz, 3H, CH3-3'''); 
EIMS (m/z): 381 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 
[C7H8NO2S]+, 155 [C7H7O2S]+, 91 [C7H7]+, 83 





Fluffy white amorphous solid; Yield: 78 %; M.P.: 
116-128 oC; Mol. formula: C17H23N3O3S2; Mol. 
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weight: 381; IR (KBr, cm-1): υmax 3065 (Aromatic 
C-H), 1651 (Oxadiazole C=N), 1535 (Aromatic 
C=C), 1336 (Sulfamoyl S=O), 1253 & 1084 
(Oxadiazole C-O-C); 1H-NMR (400 MHz, 
CDCl3,ppm): δ 7.61 (d, J = 8.0 Hz, 2H, H-2'' & H-
6''), 7.30 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 3.70-
3.65 (m, 2H, He-2' & He-6'), 3.10-3.18 (m,1H, H-
1'''), 2.86-2.79 (m, 1H, H-4'), 2.61-2.55 (m, 2H, 
Ha-2' & Ha-6'), 2.42 (s, 3H, CH3-4''), 2.11-2.07 (m, 
2H, He-3' & He-5'), 2.02-1.95 (m, 2H, Ha-3' & Ha-
5'), 1.48 (d, J = 7.2 Hz, 6H, CH3-2''' & CH3-3'''); 
EIMS (m/z): 381 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 
[C7H8NO2S]+, 155 [C7H7O2S]+, 91 [C7H7]+, 83 





White crystalline solid; Yield: 75 %; M.P.: 132-
134 oC; Mol. formula: C18H25N3O3S2; Mol. weight: 
395; IR (KBr, cm-1): υmax 3060 (Aromatic C-H), 
1642 (Oxadiazole C=N), 1528 (Aromatic C=C), 
1334 (Sulfamoyl S=O), 1244 & 1075 (Oxadiazole 
C-O-C); 1H-NMR (400 MHz, CDCl3, ppm): δ 7.60 
(d, J = 8.0 Hz, 2H, H-2'' & H-6''), 7.30 (d, J = 8.0 
Hz, 2H, H-3'' & H-5''), 3.65-3.61 (m, 2H, He-2' & 
He-6'), 3.18 (t, J = 6.8 Hz, 2H, H-1'''), 2.84-2.78 
(m, 1H, H-4'), 2.56-2.50 (m, 2H, Ha-2' & Ha-6'), 
2.41 (s, 3H, CH3-4''), 2.12-2.08 (m, 2H, He-3' & 
He-5'), 2.01-1.94 (m, 2H, Ha-3' & Ha-5'), 1.36 (qui, 
J = 6.8 Hz, 2H, H-2'''), 1.15 (sex, J = 6.8 Hz, 2H, 
H-3'''), 0.95 (t, J = 7.2 Hz, 3H, CH3-4'''); EIMS 
(m/z): 395 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 
[C7H8NO2S]+, 155 [C7H7O2S]+, 91 [C7H7]+, 83 






Grayish white amorphous solid; Yield: 74 %; 
M.P.: 125-127 oC; Mol. formula: C18H25N3O3S2; 
Mol. weight: 395; IR (KBr, cm-1): υmax 3060 
(Aromatic C-H), 1653 (Oxadiazole C=N), 1535 
(Aromatic C=C), 1344 (Sulfamoyl S=O), 1252 & 
1083 (Oxadiazole C-O-C); 1H-NMR (400 MHz, 
CDCl3,ppm): δ 7.60 (d, J = 8.0 Hz, 2H, H-2'' & H-
6''), 7.30 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 3.65-
3.61 (m, 2H, He-2' & He-6'), 3.12-3.05 (m, 1H, H-
1'''), 2.84-2.78 (m, 1H, H-4'), 2.56-2.50 (m, 2H, 
Ha-2' & Ha-6'), 2.41 (s, 3H, CH3-4''), 2.12-2.08 (m, 
2H, He-3' & He-5'), 2.01-1.94 (m, 2H, Ha-3' & Ha-
5'), 1.98 (qui, J = 6.8 Hz, 2H, H-2'''), 1.68 (d, J = 
6.8 Hz, 2H, CH3-4'''), 0.95 (t, J = 6.8 Hz, 3H, 
CH3-3'''); EIMS (m/z): 395 [M]+, 266 
[C13H16NO3S]+, 238[C12H16NO2S]+, 184 
[C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 




Fluffy white amorphous solid; Yield: 78 %; M.P.: 
120-123 oC; Mol. formula: C19H27N3O3S2; Mol. 
weight: 409; IR (KBr, cm-1): υmax 3060 (Aromatic 
C-H), 1642 (Oxadiazole C=N), 1528 (Aromatic 
C=C), 1334 (Sulfamoyl S=O), 1244 & 1075 
(Oxadiazole C-O-C); 1H-NMR (400 MHz, CDCl3, 
ppm): δ 7.60 (d, J = 8.0 Hz, 2H, H-2'' & H-6''), 
7.30 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 3.65-3.61 
(m, 2H, He-2' & He-6'), 3.18 (t, J = 6.8 Hz, 2H, H-
1'''), 2.84-2.78 (m, 1H, H-4'), 2.56-2.50 (m, 2H, 
Ha-2' & Ha-6'), 2.41 (s, 3H, CH3-4''), 2.12-2.08 (m, 
2H, He-3' & He-5'), 2.01-1.94 (m, 2H, Ha-3' & Ha-
5'), 1.36 (qui, J = 6.8 Hz, 2H, H-2'''), 1.25-1.19 
(m, 4H, H-3''' & H-4'''), 0.95 (t, J = 7.2 Hz, 3H, 
CH3-5'''); EIMS (m/z): 409 [M]+, 266 
[C13H16NO3S]+, 238 [C12H16NO2S]+, 184 
[C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 





Light yellow granular amorphous solid; Yield: 77 
%; M.P.: 115-117 oC; Mol. formula: 
C19H27N3O3S2; Mol. weight: 409; IR (KBr, cm-1): 
υmax 3058 (Aromatic C-H), 1650 (Oxadiazole 
C=N), 1531 (Aromatic C=C), 1341 (Sulfamoyl 
S=O), 1251 & 1082 (Oxadiazole C-O-C); 1H-
NMR (400 MHz, CDCl3, ppm): δ 7.61 (d, J = 8.0 
Hz, 2H, H-2'' & H-6''), 7.32 (d, J = 8.0 Hz, 2H, H-
3'' & H-5''), 3.63-3.59 (m, 2H, He-2' & He-6'), 3.10-
3.04 (m, 1H, H-1'''), 2.84-2.78 (m, 1H, H-4'), 
2.56-2.50 (m, 2H, Ha-2' & Ha-6'), 2.41 (s, 3H, 
CH3-4''), 2.12-2.08 (m, 2H, He-3' & He-5'), 2.01-
1.94 (m, 2H, Ha-3' & Ha-5'), 2.05 (q, J = 6.8 Hz, 
2H, H-2'''), 1.73 (d, J = 7.2 Hz, 2H, CH3-5'''), 1.46 
(sex, J = 6.8 Hz, 2H, CH2-3'''), 0.97 (t, J = 7.2 Hz, 
3H, CH3-4'''); EIMS (m/z): 409 [M]+, 266 
[C13H16NO3S]+, 238 [C12H16NO2S]+, 184 
[C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 





Fluffy white amorphous solid; Yield: 79 %; M.P.: 
127-129 oC; Mol. formula: C21H31N3O3S2; Mol. 
weight: 437; IR (KBr, cm-1): υmax 3055 (Aromatic 
C-H), 1655 (Oxadiazole C=N), 1531 (Aromatic 
C=C), 1335 (Sulfamoyl S=O), 1255 & 1084 
(Oxadiazole C-O-C); 1H-NMR (400 MHz, CDCl3, 
ppm): δ 7.62 (d, J = 8.0 Hz, 2H, H-2'' & H-6''), 
7.30 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 3.67-3.64 
(m, 2H, He-2' & He-6'), 3.17 (t, J = 7.2 Hz, 2H, H-
1'''), 2.86-2.81 (m, 1H, H-4'), 2.60-2.54 (m, 2H, 
Ha-2' & Ha-6'), 2.42 (s, 3H, CH3-4''), 2.11-2.07 (m, 
2H, He-3' & He-5'), 2.00-1.90 (m, 2H, Ha-3' & Ha-
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5'), 1.75 (qui, J = 7.2 Hz, 2H, H-2'''), 1.39 (qui, J 
= 7.2 Hz, 2H, H-3'''), 1.31-1.25 (m, 6H, H-4''' to 
H-6'''), 0.85 (t, J = 7.2 Hz, 3H, CH3-7'''); EIMS 
(m/z): 437 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 
[C7H8NO2S]+, 155 [C7H7O2S]+, 99 [C7H15]+, 91 





Fluffy light yellow amorphous solid; Yield: 75 %; 
M.P.: 130-132 oC; Mol. formula: C22H33N3O3S2; 
Mol. weight: 451; IR (KBr, cm-1): υmax 3050 
(Aromatic C-H), 1651 (Oxadiazole C=N), 1526 
(Aromatic C=C), 1332 (Sulfamoyl S=O), 1253 & 
1082 (Oxadiazole C-O-C); 1H-NMR (400 MHz, 
CDCl3, ppm): δ 7.61 (d, J = 8.0 Hz, 2H, H-2'' & H-
6''), 7.31 (d, J = 8.0 Hz, 2H, H-3'' & H-5''), 3.65-
3.62 (m, 2H, He-2' & He-6'), 3.17 (t, J = 7.2 Hz, 
2H, H-1'''), 2.86-2.81 (m, 1H, H-4'), 2.60-2.54 (m, 
2H, Ha-2' & Ha-6'), 2.42 (s, 3H, CH3-4''), 2.11-
2.07 (m, 2H, He-3' & He-5'), 2.00-1.90 (m, 2H, Ha-
3' & Ha-5'), 1.73 (qui, J = 7.2 Hz, 2H, H-2'''), 1.41 
(qui, J = 7.2 Hz, 2H, H-3'''), 1.33-1.28 (m, 6H, H-
4''' to H-6'''), 1.12 (sex, J = 7.2 Hz, 2H, H-7'''), 
0.89 (t, J = 7.2 Hz, 3H, CH3-8'''); EIMS (m/z): 451 
[M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 184 
[C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 
113 [C8H17]+,  91 [C7H7]+, 85 [C6H13]+, 83 
[C5H9N]+, 57 [C4H9]+, 29 [C2H5]+. 
 
Antibacterial activity  
 
The antibacterial activity results are shown in 




Compound 7a was obtained as fluffy white 
amorphous solid with molecular formula of 
C16H21N3O3S2, established through EIMS 
spectrum.  The major absorption bands in IR 
spectrum appeared at υmax (cm-1) 3065 (ar. C-H 
str.), 1563 (ar. C=C str.) & 1335 (S=O) for 
sulfamoyl moiety while 1645 (C=N), 1249 & 1079 
(C-O-C) confirmed the presence of oxadiazole 
moiety in the molecule. In EIMS spectrum 
molecular ion peak appeared at m/z 367. The 
other prominent fragments appeared at m/z 266 
for 1-(4-toluenesulfonyl)piperidin-4-
carbonylcation, at m/z 155 for 4-toluenesulfonyl 
cation and at m/z 83 for piperidine radical cation.  
 














5 85.68±1.00 54.90±0.90 55.21±0.01 55.52±0.46 34.77±0.87 
7a 72.94±0.35 70.45±0.58 69.41±0.10 44.86±0.60 76.63±0.43 
7b 71.02±0.42 67.25±0.75 68.54±0.37 63.61±0.29 73.10±0.70 
7c 66.62±0.76 64.70±0.20 67.07±0.05 58.10±0.45 72.30±0.83 
7d 59.14±1.00 53.75±0.45 56.13±0.27 62.90±0.10 66.73±0.90 
7e 72.82±0.64 55.15±0.67 53.66±0.73 52.80±0.90 64.13±0.47 
7f 73.29±0.85 55.60±0.95 51.96±0.23 56.67±0.12 62.93±0.07 
7g 67.17±0.41 45.60±0.90 30.72±0.67 49.80±0.43 50.20±0.53 
7h 63.84±0.32 59.95±0.70 64.46±0.18 45.88±0.52 69.63±0.30 
7i 32.35±0.35 49.95±0.05 42.30±0.42 13.66±0.10 64.53±0.33 
Ciprofloxacin 91.05±0.68 92.32±0.42 92.50±0.34 91.44±0.64 92.02±053 
 














5 8.10±0.41 17.41±0.18 17.21±0.23 17.98±0.51 - 
7a 9.11±0.40 9.89±0.45 9.14±0.72 - 9.11±0.60 
7b 9.63±0.51 10.56±0.65 10.20±0.45 12.78±0.55 9.43±0.10 
7c 10.34±0.61 11.21±0.78 10.16±0.31 17.20±0.68 9.87±0.19 
7d 14.39±0.31 17.54±0.09 17.61±0.24 14.59±0.62 10.55±0.52 
7e 9.22±0.81 16.43±0.12 16.54±0.50 19.28±0.67 11.46±0.69 
7f 9.10±0.10 16.14±0.65 19.01±0.14 18.97±0.38 14.86±0.15 
7g 9.89±0.48 - - - 19.70±0.20 
7h 12.63±0.56 15.98±0.10 11.20±0.31 - 9.97±0.09 
7i - - - - 12.01±0.87 
Ciprofloxacin 7.45±0.58 7.16±0.58 7.14±0.18 7.80±0.19 7.29±0.90 
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The notable fragments have also been sketched 
in Figure 1. 1H-NMR spectrum revealed ten 
resonating peaks nominating the presence of 
twenty one protons. The aromatic region of 1H-
NMR spectrum presented two doublets with two 
proton integration at δ 7.63 (J = 8.0 Hz, H-2'' & 
H-6'') and 7.31 (J = 8.0 Hz, H-3'' & H-5'') for para 
substituted phenyl ring of 4-toluenesulfony 
moiety in the molecule. In aliphatic region, four 
multiplets resonated at δ 3.69-3.64 2.60-2.54 
2.12-2.08 and 2.01-1.94 with double integration 
and one multiplet at δ 2.87-2.80 with single 
integration for piperidine moiety. One singlet at δ 
2.42 was assigned to methyl group directly 
attached to phenyl ring. The S-substituted ethyl 
group was characterized by two signals, one 
quartet and one triplet, appearing at δ 3.20 and 
1.43 The whole discussion nominated the 
molecule as 2-ethylthio-5-(1-(4-
toluenesulfonyl)piperidin-4-yl)-1,3,4-oxadiazole. 
Likewise the other nominated structures of 
synthesized molecules were elucidated and 
sketched in Table 1. 
 
The synthesized compounds were screened 
against five bacterial strains, including three 
gram-negative and two gram-positive as 
discussed in experimental section. The results 
are shown in table-2 and table-3 relative to the 
reference standard, ciprofloxacin. The MIC 
values indicated that most of the compounds are 
active against all strains under consideration. 
Compound 5 showed best activity against S. 
typhi, moderate against others and no activity 
against B. subtilis. This compound executed the 
MIC of 8.10 ± 0.41 µM relative to that of 
reference, 7.45 ± 0.58 µM against S. typhi 
bacterial strain. This was the precursor which 
was further step forwarded into some new 
molecules to check out their antibacterial 
potential. Among the substituted compounds, 7a-
f, different compounds showed different 
antibacterial potential against different bacterial 
strains. The compound, 7g possess relatively 
strong antibacterial potential against S. typhi with 
MIC 9.89 ± 0.48 with reference to ciprofloxacin 
i.e., 7.45 ± 0.58. Compound 7e-g exhibit good 
inhibitory potential against S. typhi with MIC 
values 9.22 ± 0.81, 9.10 ± 0.10 and 9.89 ± 0.48 
respectively as compared to ciprofloxacin i.e., 
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Figure 1: Mass fragmentation pattern of 2-ethylthio-5-(1-(4-toluenesulfonyl)piperidin-4-yl)-1,3,4-
oxadiazole (7a) 
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The molecule, 7a was the most active against 
the three strains, with MIC values of 9.11 ± 0.40, 
9.89 ± 0.45 and 9.14 ± 0.72 µM in comparison 
with ciprofloxacin i.e., 7.45 ± 0.58, 7.16 ± 0.58 
and 7.14 ± 0.18 µM, respectively. This molecule 
also exhibited the best activity against B. subtilis 
with MIC of 9.11 ± 0.60 µM relative to 7.29 ± 
0.90 µM, the MIC of reference. The best activity 
of this molecule might be attributed to the 
presence of ethyl group, the small aliphatic 
straight chain. The compounds, 7b-f, which 
remained active against all the strains, might be 





The synthesized molecules have been 
structurally elucidated by spectroscopic 
techniques. Molecule 7a is the strongest 
antimicrobial agents of all the synthesized 
compounds. Molecule 5 may be further subjected 
to S-substitution to obtain compounds with 
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